semaglutide soul trial oral cardiovascular outcomes 2024 2025 Oral Semaglutide Reduces Cardiovascular Events in People with Ongoing #GLP1 -RA Trials on – ACC 25 Late-Breaking Discussion: SOUL:

SGLT-2 inhibitors act primarily in the renal proximal tubule and have no established direct actions on mesolimbic reward circuits in the brain.63 On the contrary, neurotropism is a distinct property of GLP-1 receptor agonists.62 GLP-1 is produced in the brain, GLP-1 receptors are present in areas of the brain involved in impulse control and reward signalling, and a pharmacologically administered exogenous GLP-1 receptor agonist crosses the blood-brain barrier and enters the brain within minutes, strengthening the inference that the observed GLP-1 receptor agonist anti-addictive properties are likely specific and biologically plausible drug effect of GLP-1 receptor agonism, distinct from the general benefits of treating diabetes that would be expected with both SGLT-2 inhibitors and GLP-1 receptor agonists.6465 These observational findings do not by themselves justify the prescribing of GLP-1 receptor agonists specifically to prevent or treat SUDs

We also have a significant number of products that we provide to those who require materials that are of the highest of quality

It contains the active ingredient semaglutide and functions as a glucagon-like peptide-1 (GLP-1) receptor agonist, a class of drugs that mimic the action of the GLP-1 hormone, which plays a crucial role in regulating blood sugar levels

If you are looking for weight loss medication, work with a healthcare provider and explore options that are backed by research

Long-term deficiency can lead to irreversible nerve damage, dementia, and other neurological issues

doi: 10.1093/gerona/glaa185 74 AzzolinoDArosioBMarzettiECalvaniRCesariM